Log in to save to my catalogue

Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with compl...

Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with compl...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2595782880

Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101)

About this item

Full title

Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101)

Publisher

Singapore: Springer Singapore

Journal title

International journal of clinical oncology, 2021-12, Vol.26 (12), p.2216-2223

Language

English

Formats

Publication information

Publisher

Singapore: Springer Singapore

More information

Scope and Contents

Contents

Background
Adjuvant oral uracil-tegafur (UFT) has led to significantly longer postoperative survival among patients with non-small-cell lung cancer (NSCLC). Gemcitabine (GEM) monotherapy is also reportedly effective for NSCLC and has minor adverse events (AEs). This study compared the efficacy of GEM- versus UFT-based adjuvant regimens in patien...

Alternative Titles

Full title

Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2595782880

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2595782880

Other Identifiers

ISSN

1341-9625

E-ISSN

1437-7772

DOI

10.1007/s10147-021-02012-9

How to access this item